

NICHOLAS S. BRITT, PHARM.D, MS, BCPS

3901 Rainbow Blvd, MS 4047
Kansas City, KS 66160

CURRICULUM VITAE

Office: 913.588.5391
nbritt@kumc.edu

EDUCATION

- 2010-2015 **Doctor of Pharmacy** (with distinction)
University of Kansas, School of Pharmacy, Lawrence, KS
- 2013-2014 **Master of Science, Clinical Research** (with honors)
University of Kansas, School of Medicine, Kansas City, KS
Thesis: Vancomycin tolerance in *Staphylococcus aureus* bacteremia
Committee: Theresa I. Shireman, PhD, RPh (chair); Molly Steed, PharmD;
 Wissam I. El Atrouni, MD
- 2010-2013 **Bachelor of Science, Pharmaceutical Studies**
University of Kansas, School of Pharmacy, Lawrence, KS

RESIDENCY TRAINING

- 2016-2017 **PGY-2 Infectious Diseases Pharmacy Residency** (ASHP Accredited)
Barnes-Jewish Hospital, Washington University Medical Center, St. Louis, MO
Program Director: David J. Ritchie, PharmD, FCCP, BCPS (AQ-ID)
- 2015-2016 **PGY-1 Pharmacy Practice Residency** (ASHP Accredited)
Barnes-Jewish Hospital, Washington University Medical Center, St. Louis, MO
Program Director: Timothy A. Horwedel, PharmD, BCPS

CERTIFICATIONS & LICENSURES

- 2017-Present **Licensed Pharmacist**
State of Kansas – 1-100303
- 2016-Present **Board-Certified Pharmacotherapy Specialist**
Board of Pharmacy Specialties - #3153394
- 2015-Present **Advanced Cardiovascular Life Support**
American Heart Association
- 2015-Present **Basic Life Support**
American Heart Association
- 2015-Present **Licensed Pharmacist (Medication Therapy Services)**
State of Missouri - #2015024600

2015-2016 **Resident Education Academy Teaching Certificate Program**
St. Louis College of Pharmacy, St. Louis, MO
Program Directors: Jack Burke, PharmD, FASHP, FCCP, BCPS; Katie Tellor, PharmD, BCPS

PROFESSIONAL EXPERIENCE

2017-Present **Assistant Professor, Pharmacy Practice** (tenure-track)
University of Kansas, School of Pharmacy, Lawrence, KS
Dean: Kenneth L. Audus, PhD
Department Chair: David Henry, MS, BCOP, FASHP

2017-Present **Assistant Professor, Internal Medicine**
University of Kansas, School of Medicine, Division of Infectious Diseases, Kansas City, KS
Dean: Robert D. Simari, MD
Department Chair: Daniel R. Hinthorn, MD

2017-Present **Co-Director, Antimicrobial Pharmacokinetics/Pharmacodynamics Translational Research Laboratory (ASTRAL)**
University of Kansas Medical Center, Kansas City, KS

2017-Present **Clinical Pharmacist Specialist, Infectious Diseases**
University of Kansas Hospital, Kansas City, KS

2015-Present **Pharmacy Research Staff (WOC)**
Dwight D. Eisenhower Veterans Affairs Medical Center, Leavenworth, KS

2016-2017 **Infectious Diseases Pharmacy Resident**
Barnes-Jewish Hospital, Washington University Medical Center, St. Louis, MO

2015-2017 **Adjunct Clinical Instructor, Pharmacy Practice**
St. Louis College of Pharmacy, St. Louis, MO

2015-2016 **Pharmacy Practice Resident**
Barnes-Jewish Hospital, Washington University Medical Center, St. Louis, MO

PUBLICATIONS

Original Research:

- 1) Weaver KL, Shuster JE, **Britt NS**, Balsara KR, Graetz TJ, Helwani M, Itoh A, Tellor BR. Evaluation of clinical outcomes of phosphodiesterase-5-inhibitor therapy for right ventricular dysfunction after left ventricular device implantation. *American Society of Artificial and Implantable Organs (ASAIO) Journal*. 2018 [In press].
- 2) **Britt NS**, Ritchie DJ, Kollef MH, Burnham CAD, Durkin MJ, Hampton N, Micek ST. Clinical epidemiology of carbapenem-resistant Gram-negative sepsis: shifting burden of disease? *American Journal of Infection Control*. 2018 [In press].

- 3) **Britt NS**, Ritchie DJ, Kollef MH, Burnham CAD, Durkin MJ, Hampton N, Micek ST. Importance of site of infection and antibiotic selection in the treatment of carbapenem-resistant *Pseudomonas aeruginosa* sepsis. *Antimicrobial Agents and Chemotherapy*. 2018 [Epub ahead of print].
- 4) **Britt NS**, Tirmizi S, Ritchie DJ, McManus D, Topal JE, Nizet V, Casabar E, Sakoulas G. Telavancin for refractory methicillin-resistant *Staphylococcus aureus* bacteremia in intermittent hemodialysis recipients. *Journal of Antimicrobial Chemotherapy*. 2018 [Epub ahead of print].
- 5) **Britt NS**, Hagopian JC, Brennan DC, Pottebaum AA, Santos CAQ, Gharabagi A, Horwedel TA. Effects of recurrent urinary tract infections on graft and patient outcomes after kidney transplantation. *Nephrology Dialysis Transplantation*. 2017;32(10):1758-66.
- 6) **Britt NS**, Potter EM, McKinnell JA, Patel N, Battersby SE, Steed ME. Secular trends in nosomial vancomycin-resistant enterococcal bloodstream infections among United States Veterans Affairs hospitals, fiscal years 2004-2014. *Infection Control and Hospital Epidemiology*. 2017;38(9):1114-6.
- 7) Malek W, Yager J, **Britt NS**, Morse C, Hecox Z, Hoyer-Simek A, Sullivan S, Faragon J, Patel N. Clinical outcomes associated with single tablet regimens: relationship between antiretroviral therapy pill burden and control of concomitant comorbidities among HIV-infected patients. *Journal of HIV and Retrovirus*. 2017 [In press].
- 8) **Britt NS**, Potter EM, Patel N, Steed ME. Effect of continuous and sequential therapy among veterans receiving daptomycin or linezolid for vancomycin-resistant *Enterococcus faecium* bacteremia. *Antimicrobial Agents and Chemotherapy*. 2017;24;61(5).
- 9) **Britt NS**, Potter EM, Patel N, Steed ME. Comparative effectiveness and safety of low-, medium-, and high-dose daptomycin strategies in the treatment of vancomycin-resistant enterococcal bloodstream infections among Veterans Affairs patients. *Clinical Infectious Diseases*. 2017;64(5):605-613.
- 10) **Britt NS**, Shireman TI, El Atrouni WI, Horvat RT, Patel N, Steed ME. Relationship between vancomycin tolerance and clinical outcomes in *Staphylococcus aureus* bacteremia. *Journal of Antimicrobial Chemotherapy*. 2017;72(2):535-542.
- 11) **Britt NS**, Potter EM. Clinical epidemiology of vancomycin-resistant *Enterococcus gallinarum* and *Enterococcus casseliflavus* bloodstream infections. *Journal of Global Antimicrobial Resistance*. 2016;5:57-61.
- 12) **Britt NS**, Patel N, Horvat RT, Steed ME. Vancomycin area under the curve (AUC)/minimum bactericidal activity (MBC) ratio as a novel predictor of mortality in methicillin-resistant *Staphylococcus aureus* bacteremia. *Antimicrobial Agents and Chemotherapy*. 2016;60(5):3070-5.
- 13) **Britt NS**, Potter EM, Patel N, Steed ME. Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of Veterans Affairs patients. *Clinical Infectious Diseases*. 2015;61(6):871-888.

Case Reports/Case Series:

- 1) **Britt NS**, Steed ME, Potter EM, Clough LA. Tigecycline for the treatment of severe and severe complicated *Clostridium difficile* infection. *Infectious Diseases and Therapy*. 2014;3(2):321-331.

Editorials/Correspondence

- 1) **Britt NS**, Potter EM, Patel N, Steed ME. Reply to Chanderraj et al. *Clinical Infectious Diseases*. 2017 [In press].

Abstracts:

- 1) **Britt NS**, Patel N, Potter EM, Steed ME. Changing epidemiology of carbapenem-resistant *Enterobacteriaceae* bloodstream infection in United States Veterans Affairs hospitals, 2004-2014 [Abstract]. *Open Forum Infectious Diseases*. 2017 [In press].
- 2) **Britt NS**, Patel N, Potter EM, Steed ME. Polymyxin monotherapy versus combination therapy for the treatment of carbapenem-resistant *Enterobacteriaceae* bloodstream infection: a national cohort study [Abstract]. *Open Forum Infectious Diseases*. 2017 [In press].
- 3) **Britt NS**, Shireman TI, El Atrouni W, Horvat RT, Steed ME. Vancomycin tolerance and clinical outcomes in *Staphylococcus aureus* bacteremia [Abstract]. *Clinical Translational Science*. 2014;7(3): 234.

PRESENTATIONS

International/National Platform Presentations:

- 1) **Britt NS**, Ritchie DJ, Kollef MH, Durkin MJ, Hampton N, Burnham CAD, Micek ST. Comparative clinical outcomes and risk factors in carbapenem-resistant Gram-negative sepsis. American Society for Microbiology Microbe 2017 (57th Interscience Conference on Antimicrobial Agents and Chemotherapy); New Orleans, June 4, 2017.
- 2) **Britt NS**, Potter EM, Steed ME, Patel N. Clinical outcomes of methicillin-resistant *Staphylococcus aureus* bacteremia treated with ceftaroline fosamil. American Society for Microbiology Microbe 2017 (57th Interscience Conference on Antimicrobial Agents and Chemotherapy); New Orleans, June 2, 2017.
- 3) **Britt NS**, Potter EM, Patel N, Steed ME. Derivation and validation of a mortality risk assessment model for vancomycin-resistant enterococcal (VRE) bacteremia based on source of infection. American Society for Microbiology Microbe 2016 (56th Interscience Conference on Antimicrobial Agents and Chemotherapy); Boston, MA; June 19, 2016.
- 4) **Britt NS**, Potter EM, Patel N, Steed ME. Association between time to treatment and clinical outcomes in vancomycin-resistant enterococcal bloodstream infection. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, CA; September 19, 2015.

- 5) **Britt NS**, Shireman TI, El Atrouni W, Horvat RT, Steed ME. Vancomycin tolerance and clinical outcomes in methicillin-susceptible *Staphylococcus aureus* bacteremia. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC; September 6, 2014.
- 6) **Britt NS**, Shireman TI, El Atrouni W, Horvat RT, Steed ME. Vancomycin tolerance and clinical outcomes in *Staphylococcus aureus* bacteremia. Translational Science 2014 Annual Meeting; Washington, DC; April 11, 2014.

International/National Poster Presentations:

- 1) Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski E, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, **Britt NS**, Nicolau DP. Pharmacodynamics of daptomycin in combination therapy for enterococcal bloodstream infection. Infectious Diseases Society of America IDWeek 2018; San Francisco, CA, October 4, 2018.
- 2) Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski E, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, **Britt NS**, Nicolau DP. Daptomycin pharmacodynamics in patients with enterococcal bloodstream infections. American Society for Microbiology Microbe 2018 (58th Interscience Conference on Antimicrobial Agents and Chemotherapy); Atlanta, GA; June 8, 2018.
- 3) **Britt NS**, Patel N, Potter EM, Steed ME. Changing epidemiology of carbapenem-resistant *Enterobacteriaceae* bloodstream infection in United States Veterans Affairs hospitals, 2004-2014. Infectious Diseases Society of America IDWeek 2017. San Diego, CA, October 5, 2017.
- 4) **Britt NS**, Patel N, Potter EM, Steed ME. Polymyxin monotherapy versus combination therapy for the treatment of carbapenem-resistant *Enterobacteriaceae* bloodstream infection: a national cohort study. Infectious Diseases Society of America IDWeek 2017. San Diego, CA, October 7, 2017.
- 5) **Britt NS**, Ritchie DJ, Kollef MH, Durkin MJ, Hampton N, Burnham CAD, Micek ST. Comparative clinical outcomes and risk factors in carbapenem-resistant Gram-negative sepsis. American Society for Microbiology Microbe 2017 (57th Interscience Conference on Antimicrobial Agents and Chemotherapy); New Orleans, LA, June 4, 2017.
- 6) **Britt NS**, Hagopian JC, Brennan DC, Santos CAQ, Horwedel TA. Effects of recurrent urinary tract infections on graft and patient outcomes after renal transplantation. American Society for Microbiology Microbe 2017 (57th Interscience Conference on Antimicrobial Agents and Chemotherapy); New Orleans, LA, June 3, 2017.
- 7) **Britt NS**, Potter EM, Steed ME, Patel N. Clinical outcomes of methicillin-resistant *Staphylococcus aureus* bacteremia treated with ceftaroline fosamil. American Society for Microbiology Microbe 2017 (57th Interscience Conference on Antimicrobial Agents and Chemotherapy); New Orleans, LA, June 2, 2017.
- 8) **Britt NS**, Horvat RT, Steed ME. *Staphylococcus aureus* small-colony variants from cystic fibrosis sputum: optimizing isolation and vancomycin susceptibility testing. 2016 Society of Infectious Diseases Pharmacists (SIDP) Annual Meeting. Boston, MA; June 17, 2016.

- 9) **Britt NS**, Potter EM, Patel N, Steed ME. Clinical outcomes in vancomycin-resistant *Enterococcus* (VRE)/methicillin-resistant *Staphylococcus aureus* (MRSA) bloodstream coinfection treated with daptomycin or linezolid. American Society for Microbiology Microbe 2016 (56th Interscience Conference on Antimicrobial Agents and Chemotherapy); Boston, MA; June 18, 2016.
- 10) **Britt NS**, Hagopian JC, Brennan DC, Santos CAQ, Horwedel TA. Evaluation of hospitalized patients with recurrent Gram-negative urinary tract infections after kidney transplantation. University HealthSystem Consortium Annual Pharmacy Council Meeting; New Orleans, LA; December 6, 2015.
- 11) **Britt NS**, Horvat RT, Steed ME. Effect of pulmonary exposures of inhaled vancomycin on methicillin-resistant *Staphylococcus aureus* cystic fibrosis isolates in planktonic and biofilm phase. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, CA; September 20, 2015.
- 12) **Britt NS**, Steed ME, Satterwhite C, Shireman TI. Evaluation of United States Centers for Disease Control and Prevention (CDC) Guideline Concordance in the Treatment of Gonococcal Infection in Kansas Medicaid. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, CA; September 18, 2015.
- 13) **Britt NS**, Potter EM, Patel N, Steed ME. Comparative effectiveness of daptomycin versus linezolid in vancomycin-resistant enterococcal bloodstream infection: a national propensity score matched cohort study. 49th American Society of Health-System Pharmacists Midyear Clinical Meeting; Anaheim, CA; December 8, 2014.
- 14) Royal C, **Britt NS**, Steed ME. The effect of vancomycin tolerance and trough levels on clinical outcomes in methicillin-resistant *Staphylococcus aureus* bacteremia. 49th American Society of Health-System Pharmacists Midyear Clinical Meeting; Anaheim, CA; December 8, 2014.
- 15) Schroeder M, **Britt NS**, Horvat RT, Steed ME. Pharmacodynamic effect of simulated pulmonary vancomycin exposures on clinical methicillin-resistant *Staphylococcus aureus* cystic fibrosis isolates. 49th American Society of Health-System Pharmacists Midyear Clinical Meeting; Anaheim, CA; December 8, 2014.
- 16) **Britt NS**, Patel N, Horvat RT, Steed ME. Vancomycin area under the curve (AUC)/minimum bactericidal activity (MBC) ratio as a novel predictor of mortality in methicillin-resistant *Staphylococcus aureus* bacteremia. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC; September 5, 2014.
- 17) **Britt NS**, Potter EM, Patel N, Steed ME. Linezolid versus daptomycin in vancomycin-resistant enterococcal bloodstream infection. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC; September 5, 2014.
- 18) **Britt NS**, Shireman TI, El Atrouni W, Horvat RT, Steed ME. Vancomycin tolerance and clinical outcomes in *Staphylococcus aureus* bacteremia. Translational Science 2014 Annual Meeting; Washington, DC; April 11, 2014.

- 19) Bailey LJ, **Britt NS**, Steed ME. Adjunctive azithromycin for *Pseudomonas aeruginosa* ventilator-associated pneumonia. 48th American Society of Health-System Pharmacists Midyear Clinical Meeting; Orlando, FL; December 9, 2013.
- 20) **Britt NS**, Steed ME, Clough LA. Tigecycline combinations for *Clostridium difficile* infection. 48th American Society of Health-System Pharmacists Midyear Clinical Meeting; Orlando, FL; December 9, 2013.

Local/Regional Platform Presentations:

- 1) **Britt NS**, Ritchie DJ, Micek ST, Durkin M, Kollef M, Burnham CA. Impact of carbapenem resistance on patient outcomes in multidrug-resistant Gram-negative bacillus (MDR-GNB) infection. Gateway College of Clinical Pharmacy Research Symposium; St. Louis, MO; September 2016.
- 2) **Britt NS**, Hagopian JC, Brennan DC, Santos CAQ, Horwedel TA. Effects of recurrent urinary tract infections on graft and patient outcomes after renal transplantation. 7th Annual St. Louis Pharmacy Residency Research Conference; St. Louis, MO; May 2016.
- 3) **Britt NS**, Hagopian JC, Brennan DC, Santos CAQ, Horwedel TA. Effects of recurrent urinary tract infections on graft and patient outcomes after renal transplantation. Gateway College of Clinical Pharmacy Research Symposium; St. Louis, MO; September 2015.
- 4) **Britt NS**, Steed ME, Satterwhite C, Shireman TI. Evaluation of antimicrobial prescribing patterns and associated outcomes in the treatment of gonococcal infection in Kansas Medicaid. Kansas Medicaid Stakeholders Meeting; Topeka, KS; December 2013.

Local/Regional Poster Presentations:

- 1) **Britt NS**, Shireman TI, El Atrouni W, Horvat RT, Steed ME. Encore: vancomycin tolerance and clinical outcomes in *Staphylococcus aureus* bacteremia. Kansas Council of Health-System Pharmacists/Missouri Society of Health-System Pharmacists Annual Joint Meeting; Kansas City, MO; April 12, 2014.
- 2) **Britt NS**, Steed ME, Satterwhite C, Shireman TI. Evaluation of antimicrobial prescribing patterns and associated outcomes in the treatment of gonococcal infection in Kansas Medicaid. Kansas Medicaid Stakeholders Meeting; Topeka, KS; December 13, 2013.

GRANTS

National Institutes of Health (NIH) Grants:

TR000120-03 Barohn RJ, Aaronson LS (Co-PI). The Heartland Institute for Clinical and Translational Research Training Program. **Role:** Trainee. 2012 June.

Pharmaceutical Industry Grants:

Title: Comparison of monotherapy and combination therapy for the treatment of carbapenem-resistant *Enterobacteriaceae* bloodstream infection: a national cohort study of Veterans Affairs patients

Funding Source: Merck & Co, Inc.

Funding Status: Funded

Submission Date: February 2016

Role: Statistical Consultant (fee-for-service)

Principal Investigator: Molly E. Steed, PharmD, BCPS

Title: Prevalence of contraindicated drug-drug interactions between sofosbuvir/ledipasvir and ombitasvir/dasabuvir/ABT450/ritonavir ± ribavirin among patients monoinfected with hepatitis C virus

Funding Source: Gilead Sciences, Inc.

Funding Status: Funded

Submission Date: January 2015

Role: Statistical Consultant (fee-for-service)

Principal Investigator: Nimish Patel, PharmD, PhD

Title: Prevalence of contraindicated drug-drug interactions among patients coinfecting with human immunodeficiency virus and hepatitis C: comparison between sofosbuvir/ledipasvir and ombitasvir/dasabuvir/ABT450/ritonavir ± ribavirin

Funding Source: Gilead Sciences, Inc.

Funding Status: Funded

Submission Date: December 2014

Role: Statistical Consultant (fee-for-service)

Principal Investigator: Nimish Patel, PharmD, PhD

Title: Clinical outcomes associated with single tablet regimens: relationship between antiretroviral therapy pill burden and control of concomitant comorbidities among human immunodeficiency virus-infected patients

Funding Source: Gilead Sciences, Inc.

Funding Status: Funded

Submission Date: July 2014

Role: Statistical Consultant (fee-for-service)

Principal Investigator: Nimish Patel, PharmD, PhD

Foundation Grants:

Title: Evaluation of vancomycin intermediate heteroresistance, phenotypic variation, and clinical outcomes in cystic fibrosis

Funding Source: Society of Infectious Diseases Pharmacists

Funding Status: Funded

Submission Date: September 2013

Role: Study Personnel

Principal Investigator: Molly E. Steed, PharmD, BCPS

Intramural/Departmental Grants:

Title: Cellular mechanisms of Gram-positive sepsis

Funding Source: University of Kansas (New Faculty General Research Fund)

Funding Status: Pending

Submission Date: May 2018

Role: Co-Principal Investigator (Co-PI, Steven Benedict, PhD)

Title: Activity of antimicrobial combinations using a pharmacokinetic/pharmacodynamic model of cystic fibrosis lung infections

Funding Source: University of Kansas School of Pharmacy (General Research Fund)

Funding Status: Funded

Submission Date: May 2014

Role: Study Personnel

Principal Investigator: Molly E. Steed, PharmD, BCPS

TEACHING EXPERIENCE

Course Coordination:

Critical Care Series (4 credit hours) University of Kansas School of Pharmacy, Lawrence, KS Pharmacotherapy V (PHPR 665)	2018
---------------------------------------------------------------------------------------------------------------------------------------	------

Didactic Lectures/Recitations:

Cardiology/Critical Care Recitation (9 hours) University of Kansas School of Pharmacy, Lawrence, KS Pharmacotherapy V (PHPR 665)	2018
-----------------------------------------------------------------------------------------------------------------------------------------------	------

Antimicrobial Resistance (2 hours) St. Louis College of Pharmacy, St. Louis, MO Current Topics in Infectious Diseases (WE 4700)	2017
----------------------------------------------------------------------------------------------------------------------------------------------	------

Delirium in hospitalized patients (3 hours) St. Louis College of Pharmacy, St. Louis, MO Advanced Pharmacotherapy Elective (PP 5730)	2016
---------------------------------------------------------------------------------------------------------------------------------------------------	------

Antibiotic-associated diarrhea and <i>Clostridium difficile</i> infection (1 hour) University of Kansas School of Pharmacy, Lawrence, KS Pharmacotherapy III (PHPR 648)	2014
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------

Bayesian clinical trials (1 hour) University of Kansas School of Medicine, Kansas City, KS Clinical Trials (BIOS 810)	2014
------------------------------------------------------------------------------------------------------------------------------------	------

Clinical Examinations/Interprofessional Education:

Ambulatory Care II OSLE (5 hours) University of Kansas School of Pharmacy, Lawrence, KS Clinical Assessment (PHPR 670)	2018
Ambulatory Care I OSLE (5 hours) University of Kansas School of Pharmacy, Lawrence, KS Clinical Assessment (PHPR 670)	2018
Foundations of Interprofessional Collaboration: TeamSTEPPS Level 1 (4 hours) University of Kansas Medical Center, Kansas City, KS Foundations of Interprofessional Collaboration I (PHPR 541)	2018

Continuing Education (CE)/Grand Rounds Lectures:

Daptomycin dosing guidelines: review of the evidence (1 hour) University of Kansas School of Medicine Infectious Diseases Journal Club University of Kansas School of Medicine, Department of Medicine, Division of Infectious Diseases (ACCME accredited)	2018
Updates on the treatment of vancomycin-resistant enterococcal bacteremia (1 hour) Barnes-Jewish Hospital Pharmacy Journal Club and Patient Case Series St. Louis College of Pharmacy (ACPE accredited)	2017
Colistin dosing for carbapenem-resistant gram-negative infections (1 hour) Barnes-Jewish Hospital Pharmacy Journal Club and Patient Case Series St. Louis College of Pharmacy (ACPE accredited)	2017
Combination therapies for carbapenem-resistant <i>Enterobacteriaceae</i> infections (1 hour) St. Louis Pharmacy Resident Seminar Series St. Louis College of Pharmacy (ACPE accredited)	2016
<i>Candida parapsilosis</i> fungemia: azoles or echinocandins? (1 hour) Barnes-Jewish Hospital Pharmacy Journal Club and Patient Case Series St. Louis College of Pharmacy (ACPE accredited)	2016
Combination therapy for methicillin-resistant <i>Staphylococcus aureus</i> endocarditis (1 hour) Barnes-Jewish Hospital Pharmacy Journal Club and Patient Case Series St. Louis College of Pharmacy (ACPE accredited)	2016
Intensive versus standard blood pressure control (1 hour) Barnes-Jewish Hospital Pharmacy Journal Club and Patient Case Series St. Louis College of Pharmacy (ACPE accredited)	2016

- Methadone for weaning sedation in the intensive care unit** (1 hour) 2015
Barnes-Jewish Hospital Pharmacy Journal Club and Patient Case Series
St. Louis College of Pharmacy (ACPE accredited)
- Salvage therapies for methicillin-resistant *Staphylococcus aureus* bacteremia** (1 hour) 2015
St. Louis Pharmacy Resident Seminar Series
St. Louis College of Pharmacy (ACPE accredited)
- Daptomycin versus linezolid for vancomycin-resistant enterococcal bloodstream infections** (1 hour) 2015
University of Kansas School of Medicine Infectious Diseases Journal Club
University of Kansas School of Medicine, Department of Medicine, Division of Infectious Diseases (ACCME accredited)
- Vancomycin tolerance and clinical outcomes in *Staphylococcus aureus* bacteremia** (1 hour) 2014
University of Kansas School of Medicine Infectious Diseases Journal Club
University of Kansas School of Medicine, Department of Medicine, Division of Infectious Diseases (ACCME accredited)

Experiential Teaching Experience:

- Infectious Diseases (General) Rotation**, Barnes-Jewish Hospital 2017
Role: Primary preceptor
St. Louis College of Pharmacy Students (2)
Advanced Pharmacy Practice Experience (PP 6165)
- Cardiothoracic Intensive Care Rotation**, Barnes-Jewish Hospital 2016
Role: Co-preceptor
St. Louis College of Pharmacy Students (2)
Advanced Pharmacy Practice Experience (PP 6165)
- Infectious Diseases (General) Rotation**, Barnes-Jewish Hospital 2016
Role: Primary preceptor
St. Louis College of Pharmacy Student (1)
Advanced Pharmacy Practice Experience (PP 6165)
- Infectious Diseases (General) Rotation**, Barnes-Jewish Hospital 2016
Role: Co-preceptor
St. Louis College of Pharmacy Students (2)
Advanced Pharmacy Practice Experience (PP 6165)
- Infectious Diseases (General) Rotation**, Barnes-Jewish Hospital 2016
Role: Co-preceptor
St. Louis College of Pharmacy Students (2)
Advanced Pharmacy Practice Experience (PP 6165)

<p>Medical Intensive Care Unit Rotation, Barnes-Jewish Hospital <i>Role: Primary preceptor</i> St. Louis College of Pharmacy Students (4) Advanced Pharmacy Practice Experience (PP 6165)</p>	2016
<p>Internal Medicine Rotation, Barnes-Jewish Hospital <i>Role: Primary preceptor</i> St. Louis College of Pharmacy Student (1) Advanced Pharmacy Practice Experience (PP 6165)</p>	2016
<p>Medical Intensive Care Unit Rotation, Barnes-Jewish Hospital <i>Role: Co-preceptor</i> St. Louis College of Pharmacy Students (4) Advanced Pharmacy Practice Experience (PP 6165)</p>	2016
<p>Liver Transplantation Rotation, Barnes-Jewish Hospital <i>Role: Co-preceptor</i> St. Louis College of Pharmacy Students (2) Advanced Pharmacy Practice Experience (PP 6165)</p>	2015
<p>Internal Medicine Rotation, Barnes-Jewish Hospital <i>Role: Co-preceptor</i> St. Louis College of Pharmacy Student (1) Advanced Pharmacy Practice Experience (PP 6165)</p>	2015
Advising/Mentoring:	
<p>Co-Curricular Advising University of Kansas School of Pharmacy Students (6)</p>	2018

HONORS & AWARDS

2017	<p>Nominee, Pharmacotherapy Impact Paper of the Year Society of Infectious Diseases Pharmacists Nomination based on quality of research and clinical impact for Clin Infect Dis. 2017;64(5):605-613.</p>
2017	<p>American Society for Microbiology Infectious Diseases Fellow Program member based on quality of research submitted to ASM Microbe 2017.</p>
2017	<p>First Place, Significant Publications in Infectious Diseases Pharmacotherapy (2015) Most highly rated publication in infectious diseases pharmacotherapy by peers, as published in Am J Health Syst Pharm. 2017;15;74(4):238-52 for Clin Infect Dis. 2015;61(6):871-888.</p>
2016	<p>ASHP Foundation Student Research Award</p>

National award based on quality and pharmacotherapeutic impact of research conducted as a pharmacy student for *Clin Infect Dis.* 2015;61(6):871-888).

- 2016 **Pharmacotherapy Impact Paper of the Year**
Society of Infectious Diseases Pharmacists
National award based on quality of research and impact on clinical practice for *Clin Infect Dis.* 2015;61(6):871-888.
- 2016 **St Louis College of Pharmacy Resident Research Award**
Recognition based on outstanding achievement in residency research in the St. Louis metropolitan area.
- 2015 **Wolters Kluwer Clinical Communications Award**
Recognition for high academic achievement and outstanding communication skills as a graduate of the University of Kansas School of Pharmacy
- 2014 **VA Eastern Kansas Student Research Award**
Recognition for research conducted at Dwight D. Eisenhower Veterans Affairs Medical Center, Leavenworth, KS.
- 2014 **American Society for Microbiology Student and Post-Doctoral Fellows Grant**
Awarded based on quality of primary authored research submitted to the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC.
- 2014 **Translational Science 2014 Oral Presentation Award**
Award based on quality of research submitted to the Translational Science 2014 Annual Meeting, Washington, DC.
- 2013 **TL1 Clinical and Translational Research Training Program**
Competitive, mentored traineeship in clinical and translational research at the University of Kansas School of Medicine.

PROFESSIONAL SERVICE

Academic Committees:

- 2018-Present **Website/Public Affairs Workgroup**
University of Kansas School of Pharmacy, Department of Pharmacy Practice
- 2017-Present **Financial Aid/Awards Committee**
University of Kansas School of Pharmacy

Professional Organization Committees:

- 2016-Present **Recognition and Awards Committee Member**
Society of Infectious Diseases Pharmacists

2015-2017 **Research Committee Member**
Vizient/University HealthSystem Consortium

Hospital/Health System Committees:

2017-Present **Member, Antimicrobial Stewardship Subcommittee**
University of Kansas Health System, Kansas City, KS

2016-2017 **Member, Hospital Epidemiology and Infection Control Committee**
Barnes-Jewish Hospital, St. Louis, MO

2016-2017 **Member, Infectious Diseases Clinical Expert Council**
BJC HealthCare, St. Louis, MO

2015-2017 **Member, Antimicrobial Stewardship Program Task Force**
Barnes-Jewish Hospital, St. Louis, MO

2015-2017 **Member, Antibiotic Control Program**
Barnes-Jewish Hospital, St. Louis, MO

2015-2017 **Member (non-voting), Pharmacy and Therapeutics Committee**
BJC HealthCare, St. Louis, MO

2015-2017 **Member, Code Blue Emergency Response Team**
Barnes-Jewish Hospital, St. Louis, MO

2015-2017 **Member, Anti-Infective Panel**
BJC HealthCare, St. Louis, MO

2015-2017 **Member, Antimicrobial Utilization Review Committee**
Barnes-Jewish Hospital, St. Louis, MO

Professional Organizations:

2017-Present **Member, Infectious Diseases Society of America**

2015-Present **Member, American College of Clinical Pharmacy**
Critical Care Practice and Research Network (PRN)
Infectious Diseases Practice and Research Network (PRN)

2015-Present **Member, Society of Infectious Diseases Pharmacists**

2015-Present **Member, Gateway College of Clinical Pharmacy**

2014-Present **Member, American Society for Microbiology**

2012-Present **Inductee, Rho Chi Pharmaceutical Honor Society**

2010-Present **Member, American Society of Health-System Pharmacists**

2010-Present **Member, Kansas Council of Health-System Pharmacists**

2010-Present **Member, Kansas Pharmacists Association**

2010-Present **Member, American Pharmacists Association**

Manuscript Reviews:

2017-Present **Ad hoc Reviewer, *Clinical Infectious Diseases***

2017-Present **Ad hoc Reviewer, *Diagnostic Microbiology and Infectious Diseases***

2017-Present **Ad hoc Reviewer, *Critical Care Medicine***

2017-Present **Ad hoc Reviewer, *Critical Care***

2016-Present **Ad hoc Reviewer, *Pharmacotherapy***

2016-Present **Ad hoc Reviewer, *Journal of Antimicrobial Chemotherapy***

2016-Present **Ad hoc Reviewer, *Journal of Infection and Chemotherapy***

2015-Present **Ad hoc Reviewer, *Infectious Diseases and Therapy***

2015-Present **Ad hoc Reviewer, *Pharmacist's Letter***

2015-Present **Ad hoc Reviewer, *Prescriber's Letter***